Cyrus Biotechnology Appoints Jake Litwicki as VP of Engineering

Cyrus growing its team to speed biologics and small molecule
drug development software to market

SEATTLE, WA August 6, 2018 — Cyrus Biotechnology, a biotechnology software company
offering first-in-class tools for advanced protein modeling and discovery in drug development,
announced today the appointment of Jake Litwicki as VP of Engineering. Jake will lead software
engineering for the Cyrus Bench Software as a Service platform which speeds development of
new drugs and products sold to client firms in pharmaceuticals, biotechnology therapeutics,
synthetic biology and consumer products. Jake’s team will continue to grow the Cyrus Bench
toolkit, and add valuable new features including tools for antibody and biologics discovery as
well as small molecule modeling and discovery.  Prior to joining Cyrus Jake led software
engineering teams and spearheaded the transition to more modern cloud architectures at a
custom software development firm, a marketing technology startup, and most recently as the
leader of the Platform, Global and Microservice teams at Sterling Talent Solutions.
“Jake is a seasoned technical leader with experience across a variety of company and team
sizes, with a proven ability to bring widely used software to the market and to drive
improvement and best practices in an engineering organization,” said Dr. Lucas Nivon, CEO of
Cyrus. “Jake’s passion for software engineering, architecture and leadership will make him an
important part of our growth as we add scientific users at companies worldwide.”
“Cyrus is a unique organization with the potential to literally change the world for the better.
Having the opportunity to contribute to something with that kind of impact is truly inspiring”,
said Jake.  “I am eager to help grow and evolve the Cyrus team into a world leader in both
biotechnology and software as a service”, he added.

Jake’s team at Cyrus will be responsible for software frontend, backend, testing and release of
new scientific features developed by the open source RosettaCommons community, by other
Cyrus partners, or by Cyrus’s scientific software development and infrastructure team. Cyrus
software and services are currently being utilized by multiple companies including 10 of the top
20 Global Pharmaceutical firms, not only to design new drugs but also to offer solutions for
problems in drugs already under development.

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein
modeling and design capabilities to the Biotechnology, Pharmaceutical, Chemical, Consumer
Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the
University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for
protein structure prediction, modeling, stabilization, engineering and design to accelerate
discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta
software package from Prof. David Baker’s lab at the University of Washington, along with
associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline
of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP
competition and the weekly CAMEO competition, as well as the only protein engineering
software experimentally proven to design new proteins completely via software.. Cyrus in
financed by leading investors in both Technology and Biotechnology, including Trinity Ventures,
Orbimed, Springrock Ventures, Alexandria Venture Investments, the W Fund, and others.

Cyrus is featured in: Built In Seattle’s 50 Startups to Watch in 2018

Cyrus Biotechnology offers molecular scientists a cloud-based platform that allows them to design and build protein molecules. The software is based on a protein-modelling platform called Rosetta, which was first conceived and created at the University of Washington, and essentially allows the creation of entirely new types of proteins inside a computer. Cyrus Biotechnology brings this capability to the market with a software package which includes, among other things, a visual representation of proteins as a user constructs them.

Click here for full article.

Cyrus Biotechnology Launches Immune Epitope Prediction Software

SEATTLE  Cyrus Biotechnology, Inc., a Seattle-based firm offering access to Rosetta, the most advanced software available for protein modeling and accelerated drug discovery, announced today the general release of a new immune screening and prediction tool in their Cyrus Bench® platform.

Cyrus customers can now drastically reduce immunogenicity in pre-clinical candidates, thereby decreasing the chance of dangerous and costly adverse events during clinical trials.

Published work has demonstrated the effectiveness of combining this epitope prediction method with the powerful protein design algorithms in Rosetta. Two published examples show positive proof of drastic immunogenicity reduction, both in mice and ex vivo in human test subjects. Cyrus has carried out a third such study with an academic collaborator, which has been experimentally proven in animal models. The details of this study will be published separately.

The epitope prediction software is based on the carefully curated set of known MHC-II epitopes in the IEDB database. Those data were used to train a modern Machine Learning algorithm to detect likely new epitopes in proteins of interest. The algorithm was then refined with experimental data to confirm its scientific validity.

The immune epitope prediction and protein design algorithms are currently available to existing subscribers to Cyrus Bench® and can be accessed by new customers by subscribing to the Cyrus Bench® suite of tools.

Cyrus will introduce a novel, fully automated immune epitope removal software tool in the next few months as another valuable addition to the rapidly expanding capabilities in Cyrus Bench®. It will be the first commercially available software-based method proven to reduce immune liabilities in candidate biologics or already marketed biologics.

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 700 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus in financed by experienced investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Real Estate, the W Fund, and others.

NOTICE: The information contained in this document is dated as of July 10, 2018. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Business Wire Release July 10, 2018

Contacts

Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com

Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, April 30th – May 3rd

SEATTLE, April 18, 2018 — Cyrus Biotechnology, Inc., a biotechnology software company offering the most advanced protein modeling and design capabilities to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation in the 14th Annual PEGS Boston Protein Engineering Summit in Boston, from April 30th through May 3rd.

Dr. David Pearlman, Senior Fellow and Director of Customer Experience at Cyrus Bio, and Rosario Caltabiano, Executive VP of Sales, will attend the conference and discuss the latest advances in in silico protein engineering at booth 539 in the Boston Seaport World Trade Center Exhibit Hall. 

The Rosetta software package, from the RosettaCommons, is the premier software platform for advanced computational protein engineering. Cyrus has implemented the Rosetta stack with an easy to use interface on a public computing cloud, resulting in high reliability software with high performance and usability in a secure multi-tenant model. R&D organizations can remove large capital expenditures, avoid over- or under-provisioning, and maximize scientific output.

In silico modeling and design of proteins is becoming increasingly relevant to the pharmaceutical industry, as investment in research, development and clinical trials of biologic therapeutics continues to grow. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations and are at the nexus of this major trend. Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Protein Stabilization
  • Computational Affinity Maturation (Interface Design)
  • Prediction of Immunogenic Epitopes
  • Removal of Identified Liabilities
  • Protein Structure Optimization and Design
  • Antibody Engineering
  • Antigen Design

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others.

NOTICE: The information contained in this document is dated as of April 18, 2018.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 04/18/2018

 

Contact Lucas Nivon
lucas@cyrusbio.com
206-258-6561

Cyrus Bio Co-Founder David Baker Featured in the New York Times

SEATTLE, WA January 02, 2018 — Prof. David Baker, Cyrus Bio Scientific Co-Founder and Director of the Institute for Protein Design at the University of Washington, and the Rosetta software, have been prominently featured in the December 26th, 2017 New York Times article by Carl Zimmer, “Scientists are Designing Artisanal Proteins for Your Body.”

The article illustrates how computationally building proteins from first principles are effectively targeting influenza, botulism, opioids, gluten intolerance, gene therapy and immuno-oncology.

Gary Nabel, Chief Scientific Officer at Sanofi, is quoted saying that “the new research may lead to the invention of molecules we can’t yet imagine.”

Cyrus Bench® is a Software-as-a-Service platform based on the Rosetta protein modeling toolkit for protein structure prediction, discovery, modeling, stabilization, engineering and design, making some of the methods developed at Prof. Baker’s lab available to a wider audience of scientific users in Pharmaceutics, Chemicals, Consumer Products, Academia and Non-Profits.

Click here to access the article. A subscription to the New York Times may be required.

 

Cyrus Biotechnology to Present at the Biotech Showcase™ Annual Conference on January 9, 2018

Cyrus Bio technology can speed new drug discovery

 

SEATTLE, WA December 29, 2017 — Cyrus Biotechnology, a biotechnology software company offering first-in-class tools for advanced protein modeling and discovery in drug development, announced today that it will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.

 

Dr. Lucas Nivon, CEO, will present at the Biotech Showcase™ as follows:

Date: Tuesday, January 9th, 2018

Time: 2:00PM PST

Room: Franciscan D (Ballroom Level)

Venue:  Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

 

Cyrus offers Bench®, a Software-as-a-Service platform for protein structure prediction, biologics discovery, alternative structure modeling, protein stabilization, engineering and design, along with custom software development and experienced scientific support services in computational protein engineering.

 

Bench® is based on two decades of work in computational biophysics and the first software algorithms to design new proteins in a computer. It has been designed for a wider range of users than previous academic-based software. Cyrus is rapidly acquiring customers ranging from Fortune 500 Pharma (including eight of the top 20 Pharma firms), chemical and consumer products firms to privately-held biotech and synthetic biology firms.

 

Bench® is a graphical, cloud-enabled version of the Rosetta protein modeling toolkit. Data generated from Rosetta technology can be used in the design of new potential therapeutics, such as a therapeutic protein of Tocagen’s Toca 511 and PVP Biologics’ KumaMax, an oral enzyme. Cyrus is funded by leading investors in both Tech and Biotech sectors, led by Trinity Ventures with Orbimed, SpringRock, W Fund and others.

 

“We are very excited to be presenting at Biotech Showcase™,” said Cyrus CEO Dr. Lucas Nivon. “Year after year, our participation in the J.P. Morgan Annual Healthcare Conference has been fruitful and productive for the organizations we have established partnerships with. Our Bench® technology broadens access to the most advanced biocomputational methods, giving more scientists the means to speed their research and save costs. The result is more effective drugs getting to patients sooner.”

 

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

 

Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Cyrus Biotechnology will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others…

 

NOTICE: The information contained in this document is dated as of December 29, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 12/29/2017

 

Contact Lucas Nivon
lucas@cyrusbio.com
206-258-6561

 

Cyrus Biotechnology Appoints Dr. David A Pearlman as Senior Fellow and Director of Customer Experience

Cyrus technology can speed new drug discovery

SEATTLE, WA November 20, 2017 — Cyrus Biotechnology, a biotechnology software company offering first-in-class tools for advanced protein modeling and discovery in drug development, announced today that it has appointed David Pearlman, Ph.D. as Senior Fellow and Director of Customer Experience.  Dr. Pearlman will lead scientific customer interactions with Cyrus’s client firms in pharmaceuticals, biotechnology therapeutics, synthetic biology and consumer products, creating a unified customer experience team. Dr. Pearlman’s team will guide users towards creating enhanced value through new engineered proteins and other compounds for a wide variety of indications using Cyrus technology.  Prior to joining Cyrus, Dr. Pearlman’s industry role was Senior Scientist and Director of Biologics Software Platform at Schrödinger, LLC, a leader in chemical simulation software and services.

 

“David has a track record of scientific innovation and market-savvy product creation in molecular modeling software that is unique. We are very fortunate to add him to our leadership team at Cyrus”, said Dr. Lucas Nivon, CEO of Cyrus. “He has played a critical role in the creation and growth of a number of innovative and market-leading firms, and has the unique blend of deep scientific understanding and customer-centric product development that will be important for Cyrus as we engage with a rapidly expanding set of customers.”

 

“The ability of computational chemistry to make significant contributions to molecular discovery has grown tremendously over my career.” said Dr. Pearlman.  “We’re now at a point where understanding, methods and computational resources are having real, measurable impact on new drug discovery. I’m particularly excited to be at Cyrus, where we are commercializing the world-class Rosetta protein design tools. The Rosetta platform has been at the heart of an incredible number of defining protein design studies over the past couple of decades.” Pearlman added.

 

Dr. Pearlman is a pioneer in the field of computational chemistry. He was a founding product manager at Biosym Technologies (later BIOVIA), an early employee of Vertex Pharmaceuticals, and led development of the biologics software platform (BioLuminate) at Schrödinger, LLC. He was also, for many years, first author and a principal developer of the widely-used AMBER simulation platform. He has published a long string of seminal papers in the area of free energy perturbation, and extensively on topics such as NMR refinement and de novo ligand design and scoring.

 

Background

Cyrus Biotechnology

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition and the weekly CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software. Cyrus Bench is based on over 15 years of biochemistry software development and over 400 published papers demonstrating experimental efficacy in vitro and in vivo. Cyrus is funded by experienced investors in Tech and Biotech including Trinity Ventures, Orbimed Advisors, SpringRock Ventures, W Fund and others…

 

NOTICE: The information contained in this document is dated as of November 20, 2017.  Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date.  This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties.  Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Cyrus Press Release 11/20/2017

 

Contact Lucas Nivon
lucas@cyrusbio.com
206-258-6561

 

Cyrus Bio Featured in US Pharmaceutical Industry Weekly Report

Cyrus Bio CEO, Lucas Nivon, was interviewed by MSA Partners for the October 20, 2017 issue of the US Pharmaceutical Industry Weekly Report. Please contact MSA Partners to subscribe to the newsletter.

About MSA Partners
Founded in 1983, MSA Partners’ mission is to provide Japanese organizations with means and ways to realize and grow their business potential in the US market. As the challenges faced by Japanese organizations doing business in the US have grown increasingly complex over the years, MSA’s integrated and creative approach has become ever more valuable to its clients. MSA takes a team-based approach to combine the skills and expertise of both American and Japanese professionals from MSA, supplement these with outside skills when necessary, and work closely with clients to accomplish their goals. With over 25 years of experience, MSA offers a diverse range of interrelated research, consulting, communications and positioning services, to provide in-depth, comprehensive support to clients. Recognizing that one of the keys to quickly seizing market opportunities is overcoming organizational and language barriers, MSA’s ability to seamlessly interface with our clients at both the head office and US subsidiary level facilitates shared understanding and decision-making.

Cyrus Bio Leads Computational Protein Engineering Panel

SEATTLE, October 17, 2017 — Lucas Nivon, CEO of Cyrus Biotechnology, today will lead a panel on recent advances in computational protein engineering at LabCentral in Cambridge, MA.

 

Computationally designed therapeutic proteins are in the clinic, and computationally optimized enzymes are producing ingredients of value sustainably and cost effectively. Dr. Nivon will present an overview of published and experimentally verified advances in computational protein engineering, and will demonstrate some modeling workflows with sample software based on the Rosetta protein modeling toolkit first developed at Professor David Baker’s laboratory at the University of Washington. Following Dr. Nivon’s overview, four panelists from Manus Biosynthesis, Moderna Therapeutics, Northeastern University and UMass Dartmouth will present various examples of protein modeling.

 

In addition to LabCentral, this event has been publicized on Mass Bio and Mass Life Sciences Center web sites.

 

Click here for registration and full abstracts.